Nektar Therapeutics (NKTR)
(Delayed Data from NSDQ)
$22.96 USD
+1.28 (5.90%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $23.20 +0.24 (1.05%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
NKTR 22.96 +1.28(5.90%)
Will NKTR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for NKTR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NKTR
NKTR Stock Soars as Lead Drug Meets Goal in Atopic Dermatitis Study
Strength Seen in Nektar (NKTR): Can Its 12.1% Jump Turn into More Strength?
NKTR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Nektar Q1 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down
Nektar Therapeutics (NKTR) Reports Q1 Loss, Lags Revenue Estimates
Will Nektar Therapeutics (NKTR) Report Negative Q1 Earnings? What You Should Know
Other News for NKTR
Nektar to Announce Financial Results for the Second Quarter on Thursday, August 7, 2025, After ...
Nektar gets FDA fast track status for alopecia areata drug
Nektar (NKTR) Gains FDA Fast Track Status for Alopecia Areata Treatment
Nektar's rezpegaldesleukin granted Fast Track Designation in alopecia areata
Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of ...